Moffitt Cancer Center
Clarified Precision Medicine Acquires Molecular Diagnostics Firm Interpares Biomedicine
The acquisition brings Interpares' genetic sequencing test, OncoGuardian, into Clarified's portfolio of precision medicine products.
Apis Assay Technologies, Moffitt Cancer Center to Evaluate RNA Biomarkers for Cancer Progression
The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.
Blood-Based Genetic Risk Score Shows Promise for Prostate Cancer Drug Response, Survival Prediction
Premium
The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
New Coalition, Stakeholder Groups Push Back Against FDA 'Backdoor' Attempts to Regulate PGx Tests
Premium
While some groups have communicated their concerns directly to the agency, stakeholders have also formed a new coalition to publicly take issue with FDA's actions.
Sep 20, 2017
Hearst Invests $75M in M2Gen
Aug 11, 2015
Sep 23, 2014